Navigation Links
Stem Cell / Regenerative Medicine & HSCT / Cord Blood Market Analysis in New Research Report at ReportsnReports.com
Date:3/12/2013

Dallas, TX (PRWEB) March 12, 2013

This comprehensive market report has primarily focused on quantitative market metrics in order to characterize the growth and evolution of the cellular therapy field--in this vein. The report provides primary industry data that it has collected as part of its continual industry tracking of this space.

The report analysis clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. The report also presents the breakout of clinical trials in the bonafide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.

The report “Cellular Therapy and Cord Blood 2013 Market Report” also provides a detailed quantitative analysis of the cord blood field as it is rapidly evolving. The report provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, the report has been able to compare the EU and US markets side-by-side in this analysis.

The report also presents the ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union. Details on the statute as well as implications to companies seeking to navigate this space are provided.

Extensive Market Analyses Presented in this Report:

  •     Regenerative Medicine and Stem Cell Research Activity in the US
  •     Sales of Commercial Products and Services in Stem Cell/Regenerative Medicine Sectors
  •     Breakout of Spending by Companies in the Cellular Therapy/Regenerative Medicine Space
  •     Breakout of Spending by Product Platforms in Various Spaces
  •     Autologous vs. Allogeneic Business Models in the Cellular Therapy Space
  •     Autologous vs. Allogeneic Cellular Therapy: Industry SWOT
  •     Adult Stem Cell Therapy Quantitative Market Forecast
  •     Cellular Therapy Product Pipeline
  •     Clinical Trials Quantitative Metrics and Detailed Breakout by Phase, Cell Type, Therapeutic

Areas Addressed, Geography

  •     HSCTs Performed in the EU: Percent Breakout by Disease Classes Addressed
  •     Indications for HSCTs in North America: Disease Classes Addressed, Age of Recipients, Types of HSCs Utilized, Classes of Transplant Inoculum
  •     Cost Analyses of HSCTs in the EU vs. US Markets
  •     Cord Blood Banking Quantitative Market Metrics
  •     Growth of BM, PBL, and CB Units Worldwide in Public Banks and Registries, Segmented by Country
  •     Cord Blood Transplantation Trends: Age of Recipient, Disease Classes Addressed
  •     EU and US Cord Blood Transplantation Detailed Cost Breakouts
  •     EU ATMP Regulation Detailed Analysis
  •     Stem Cells Worldwide Publications Analysis

Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=225107.

Table of Contents:
Chapter I Cellular Therapeutics Market Landscape
Chapter II Cord Blood Market Landscape
Chapter III Stem Cell Opportunities and Funding Sources in Some of the Top Markets across the European Union
Chapter IV ATMP Regulatory Routes for Approval of Cellular Therapies in the European Union

Explore more reports Biotechnology Market and Stem Cell Market.

About US:
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/stem-cell-regenerative/cord-blood-market/prweb10521610.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
2. ODT Forum Presents Regenerative Technologies
3. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
4. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
5. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
6. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
7. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte
11. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):